Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. (Q48374137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Richard Weisler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Joel Young

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Greg Mattingly

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Joseph Gao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Liza Squires

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

304 Study Group

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

573-585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

Sleep and sleep disorders in adults with attention deficit/hyperactivity disorder

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

The ADHD and sleep conundrum: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

A simulated workplace experience for nonmedicated adults with and without ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Sleep disturbances associated with attention deficit hyperactivity disorder: the impact of psychiatric comorbidity and pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Stimulant rebound: how common is it and what does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Combination pharmacotherapy for adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

A clinical perspective of attention-deficit/hyperactivity disorder into adulthood

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024056

7 January 2021

10.1017/S1092852900024056

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20095369%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference